CVRx, Inc. (CVRX)

Market Cap	360.60M
Revenue (ttm)	51.29M
Net Income (ttm)	-59.97M
Shares Out	26.04M
EPS (ttm)	-2.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	207,552
Open	14.14
Previous Close	14.01
Day's Range	13.41 - 14.14
52-Week Range	6.40 - 22.50
Beta	1.25
Analysts	Strong Buy
Price Target	17.83 (+28.74%)
Earnings Date	Feb 4, 2025

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: CVRX
• Website: https://www.cvrx.com

Financial Performance

In 2024, CVRx, Inc.'s revenue was $51.29 million, an increase of 30.53% compared to the previous year's $39.30 million. Losses were -$59.97 million, 45.5% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for CVRX stock is "Strong Buy." The 12-month stock price forecast is $17.83, which is an increase of 28.74% from the latest price.

Price Target

$17.83

(28.74% upside)

Analyst Consensus: Strong Buy